Epidermal growth factor receptor antagonists - Pipeline Insight, 2024

This “Epidermal Growth Factor Receptor Antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Epidermal Growth Factor Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Epidermal Growth Factor Receptor Antagonists Understanding

Epidermal Growth Factor Receptor Antagonists: Overview

Epidermal growth factor (EGF) is a 53-amino-acid cytokine which is proteolytically cleaved from a large integral membrane protein precursor. EGF acts to stimulate growth of epithelial cells, accelerates tooth eruption and eyelid opening in mice, inhibits gastric acid secretion and is involved in wound healing.

Function - The epidermal growth factor family of receptor tyrosine kinases (ErbBs) plays essential roles in regulating cell proliferation, survival, differentiation and migration. The ErbB receptors carry out both redundant and restricted functions in mammalian development and in the maintenance of tissues in the adult mammal. Loss of regulation of the ErbB receptors underlies many human diseases, most notably cancer.

Epidermal Growth Factor Receptor Antagonists - EGFR inhibitor was the first agent developed as a target cancer therapy. Two classes of EGFR inhibitors are in current use: the monoclonal antibodies that target the extracellular ligand-binding domain and small-molecule tyrosine kinase inhibitors (which target intracellular domain. EGFR inhibitors have been approved for the treatment of metastatic non-small-cell lung cancer, colorectal cancer, pancreatic cancer, and squamous cell carcinoma of the head and neck. When the expression of EGFR is decreased, inhibition of downstream signaling occurs in malignant tumor cells. This results in inhibition of metastasis, growth, proliferation, differentiation, and angiogenesis and causing apoptosis of cancer cells.

Epidermal Growth Factor Receptor Antagonists Emerging Drugs Chapters

This segment of the Epidermal Growth Factor Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Epidermal Growth Factor Receptor Antagonists Emerging Drugs

Nazartinib: Novartis OncologyNovartis Oncology (previously Novartis) is developing nazartinib (formerly EGF 816), a third generation mutant-selective tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), for the treatment of solid malignancies, with a focus on non-small cell lung cancer. Nazartinib is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min-1 on EGFR(L858R/790M) mutant, respectively. Upon oral administration, nazartinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. Currently, it is in phase 3 stage of development for the treatment of Non-small cell lung cancer.

Zorifertinib: AstraZenecaZorifertinib (AZD-3759) is an oral inhibitor of both wild-type and mutant EGFR with IC50 values in nanomolar range. The drug was discovered by AstraZeneca for the treatment of non-small-cell lung cancer with CNS metastases. AZD-3759 can penetrate the blood-brain barrier and was confirmed to be effective in vitro with NSCLC cell lines as well as in mouse model of brain metastases.

Epidermal Growth Factor Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Epidermal Growth Factor Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Epidermal Growth Factor Receptor Antagonists

There are approx. 30+ key companies which are developing the Epidermal Growth Factor Receptor Antagonists. The companies which have their Epidermal Growth Factor Receptor Antagonists drug candidates in the most advanced stage, i.e. phase III include, Novartis Oncology.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Epidermal Growth Factor Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Epidermal Growth Factor Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Epidermal Growth Factor Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Epidermal Growth Factor Receptor Antagonists drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Epidermal Growth Factor Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Epidermal Growth Factor Receptor Antagonists.

Epidermal Growth Factor Receptor Antagonists Report Insights

• Epidermal Growth Factor Receptor Antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Epidermal Growth Factor Receptor Antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Epidermal Growth Factor Receptor Antagonists drugs?
• How many Epidermal Growth Factor Receptor Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Epidermal Growth Factor Receptor Antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Epidermal Growth Factor Receptor Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Epidermal Growth Factor Receptor Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis Oncology
• AstraZeneca
• Voronoi
• Blueprint Medicines
• Symphogen
• Hutchison Medipharma
• Beta Pharma
• Checkpoint Therapeutics
• InventisBio
• XuanZhu Pharma
• Allist Pharmaceuticals
• ACEA Therapeutics
• Astellas Pharma
• Sunshine Lake Pharma
• Hangzhou ACEA Pharmaceutical Research
• Black Diamond Therapeutics
• Zentalis Pharmaceuticals
• Glycotope
• Sinocelltech
• Pfizer
• Cullinan Oncology
• Merus
• ARIAD Pharmaceuticals
• Jiangsu Hengrui Medicine
• Tianjin Hemay Biotech
• Shanghai Henlius Biotech
• Sichuan Kelun Pharmaceutical Research Institute

Key Products

• Nazartinib
• Zorifertinib
• ORIC 114
• BLU 945
• Futuximab/modotuximab
• Epitinib
• Rezivertinib
• Olafertinib
• D 0316
• Pirotinib
• Alflutinib
• Abivertinib
• Osimertinib
• Erlotinib
• Gefitinib
• Larotinib
• Avitinib
• BDTX 189
• ZN e4
• Tomuzotuximab
• SCT 200
• Dacomitinib
• CLN 081
• MCLA 129
• Mobocertinib
• Pyrotinib
• PB 357
• Hemay 022
• Cetuximab biosimilar
• KL 140

This product will be delivered within 1-3 business days.